'Frustrated and confused' by PBAC

Posted 26 August 2025 AM

Rare Cancers Australia has joined the growing pushback against the PBAC, expressing frustration and confusion over its failure to act on a multi-cancer funding model.

It follows a decision by the Committee to reject an application by MSD for a broad listing for all TGA-registered indications for its blockbuster drug Keytruda, pointing out the model would exclude some patients with rare cancers.

To see the whole article please log in.

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here